X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oxaliplatin (3737) 3737
humans (3395) 3395
oncology (2786) 2786
index medicus (2748) 2748
male (2455) 2455
female (2415) 2415
chemotherapy (2391) 2391
middle aged (2240) 2240
aged (2198) 2198
cancer (1736) 1736
adult (1705) 1705
antineoplastic combined chemotherapy protocols - therapeutic use (1654) 1654
colorectal cancer (1561) 1561
fluorouracil (1409) 1409
antineoplastic combined chemotherapy protocols - adverse effects (1378) 1378
colorectal neoplasms - drug therapy (1314) 1314
organoplatinum compounds - administration & dosage (1229) 1229
treatment outcome (1213) 1213
leucovorin (1136) 1136
organoplatinum compounds - adverse effects (1077) 1077
fluorouracil - administration & dosage (1050) 1050
colorectal neoplasms - pathology (953) 953
irinotecan (898) 898
metastasis (798) 798
capecitabine (796) 796
aged, 80 and over (785) 785
1st-line treatment (763) 763
care and treatment (757) 757
antineoplastic agents - adverse effects (736) 736
disease-free survival (717) 717
bevacizumab (703) 703
pharmacology & pharmacy (700) 700
5-fluorouracil (686) 686
antineoplastic combined chemotherapy protocols - administration & dosage (684) 684
medicine & public health (684) 684
fluorouracil - adverse effects (675) 675
deoxycytidine - analogs & derivatives (674) 674
leucovorin - administration & dosage (654) 654
survival (629) 629
trial (610) 610
cisplatin (594) 594
therapy (585) 585
surgery (580) 580
research (578) 578
camptothecin - analogs & derivatives (549) 549
deoxycytidine - administration & dosage (525) 525
combination (510) 510
neoplasm staging (503) 503
organoplatinum compounds - therapeutic use (501) 501
retrospective studies (483) 483
antineoplastic agents - therapeutic use (474) 474
clinical trials (469) 469
neoplasm metastasis (460) 460
analysis (459) 459
antineoplastic agents (449) 449
drug administration schedule (446) 446
camptothecin - administration & dosage (427) 427
patients (423) 423
cancer therapies (422) 422
drug therapy (420) 420
adenocarcinoma - drug therapy (419) 419
antimitotic agents (417) 417
fluorouracil - therapeutic use (414) 414
survival rate (411) 411
leucovorin - adverse effects (410) 410
fluorouracil - analogs & derivatives (406) 406
liver neoplasms - secondary (402) 402
cetuximab (393) 393
gemcitabine (389) 389
prognosis (380) 380
cancer research (375) 375
survival analysis (369) 369
hematology, oncology and palliative medicine (360) 360
toxicity (358) 358
carcinoma (354) 354
antineoplastic agents - administration & dosage (349) 349
colorectal neoplasms - mortality (348) 348
metastatic colorectal-cancer (347) 347
liver neoplasms - drug therapy (346) 346
animals (344) 344
deoxycytidine - adverse effects (329) 329
health aspects (326) 326
phase-ii (317) 317
colorectal-cancer (314) 314
cancer patients (303) 303
tumors (301) 301
pharmacology/toxicology (297) 297
kaplan-meier estimate (294) 294
folinic acid (291) 291
adenocarcinoma (285) 285
metastases (284) 284
chemotherapy, adjuvant (280) 280
gastroenterology & hepatology (278) 278
dose-response relationship, drug (275) 275
neurotoxicity (272) 272
risk factors (271) 271
colorectal carcinoma (270) 270
stomach neoplasms - drug therapy (268) 268
leucovorin - therapeutic use (265) 265
randomized-trial (260) 260
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4195) 4195
Japanese (53) 53
French (19) 19
German (14) 14
Chinese (10) 10
Spanish (7) 7
Korean (3) 3
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Clinical Oncology, ISSN 1759-4774, 10/2009, Volume 6, Issue 10, pp. 596 - 603
Historically, body tissues with a high rate of cell turnover, such as the bone marrow, have been most susceptible to chemotherapy-induced damage. The... 
PHASE-II TRIAL | ONCOLOGY | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | ALBUMIN-BOUND PACLITAXEL | BRAIN-TUMOR CONSORTIUM | ACUTE TRANSIENT ENCEPHALOPATHY | CEREBROSPINAL-FLUID PHARMACOKINETICS | OXALIPLATIN-RELATED NEUROTOXICITY | RECURRENT MALIGNANT GLIOMAS | ANALOG IXABEPILONE BMS-247550 | ADVANCED COLORECTAL-CANCER | Dacarbazine - adverse effects | United States | Humans | Antibodies, Monoclonal - adverse effects | Boronic Acids - adverse effects | Drug Approval | Epothilones - adverse effects | Bevacizumab | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Dacarbazine - analogs & derivatives | Pyrroles - adverse effects | Angiogenesis Inhibitors - adverse effects | United States Food and Drug Administration | Tubulin Modulators - adverse effects | Bortezomib | Clinical Trials as Topic | Imatinib Mesylate | Piperazines - adverse effects | Neoplasms - drug therapy | Neurotoxicity Syndromes - etiology | Indoles - adverse effects | Pyrazines - adverse effects | Pyrimidines - adverse effects | Benzamides | Antineoplastic Agents, Alkylating - adverse effects | Organoplatinum Compounds - adverse effects | Antimitotic agents | Complications and side effects | Nervous system diseases | Patient outcomes | Dosage and administration | Genetic aspects | Research | Antineoplastic agents | Drug therapy | Risk factors | Cancer | Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors
Journal Article
Annals of Oncology, ISSN 0923-7534, 05/2005, Volume 16, Issue 5, pp. 762 - 766
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 07/2014, Volume 12, Issue 7, pp. 1028 - 1059
The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance,... 
PHASE-III TRIAL | GROWTH-FACTOR RECEPTOR | UNRESECTABLE LIVER METASTASES | BEVACIZUMAB-CONTAINING ARMS | ONCOLOGY | HIGH-DOSE LEUCOVORIN | POSTPROGRESSION SURVIVAL-TIME | 1ST-LINE COMBINATION CHEMOTHERAPY | KRAS WILD-TYPE | CAPECITABINE PLUS OXALIPLATIN | METASTATIC COLORECTAL-CANCER | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colonic Neoplasms - drug therapy | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Bevacizumab | Colonic Neoplasms - surgery | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Deoxycytidine - adverse effects | Leucovorin - therapeutic use | Cetuximab | Liver Neoplasms - secondary | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Camptothecin - therapeutic use | Fluorouracil - analogs & derivatives | Membrane Proteins - genetics | Liver Neoplasms - drug therapy | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 04/2018, Volume 2018, Issue 4, pp. CD011746 - CD011746
Background Biliary tract cancers are a group of rare heterogeneous malignant tumours. They include intrahepatic and extrahepatic cholangiocar-cinomas,... 
MEDICINE, GENERAL & INTERNAL | INTRAHEPATIC CHOLANGIOCARCINOMA | RISK-FACTORS | RANDOMIZED PHASE-II | DESIGN CHARACTERISTICS | FINDINGS TABLES | EMPIRICAL-EVIDENCE | GALLBLADDER CANCER | POOLED ANALYSIS | SINGLE-AGENT GEMCITABINE | TRIAL SEQUENTIAL-ANALYSIS | Capecitabine - administration & dosage | Gallbladder Neoplasms - mortality | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Biliary Tract Neoplasms - mortality | Ampulla of Vater | Cisplatin - administration & dosage | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Oxaliplatin | Deoxycytidine - adverse effects | Female | Quinazolines - administration & dosage | Biliary Tract Neoplasms - drug therapy | Biliary Tract Neoplasms - pathology | Mitomycin - adverse effects | Piperidines - administration & dosage | Tegafur - adverse effects | Cholangiocarcinoma - mortality | Oxonic Acid - administration & dosage | Oxonic Acid - adverse effects | Randomized Controlled Trials as Topic | Antimetabolites, Antineoplastic - therapeutic use | Cholangiocarcinoma - pathology | Gallbladder Neoplasms - drug therapy | Capecitabine - adverse effects | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Piperidines - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Quinazolines - adverse effects | Cisplatin - adverse effects | Tegafur - administration & dosage | Gallbladder Neoplasms - pathology | Mitomycin - administration & dosage | Deoxycytidine - analogs & derivatives | Drug Combinations | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 08/2016, Volume 27, Issue 8, pp. 1539 - 1546
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 38 - 47
Summary Background Neoadjuvant chemotherapy for unresectable colorectal liver metastases can downsize tumours for curative resection. We assessed the... 
Hematology, Oncology and Palliative Medicine | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | BEVACIZUMAB | GUIDELINES | OXALIPLATIN | FLUOROURACIL | COMBINATION | HEPATIC RESECTION | CANCER | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Tomography, Spiral Computed | Liver Neoplasms - chemistry | Hepatectomy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Austria | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Female | Leucovorin - therapeutic use | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Cetuximab | Liver Neoplasms - secondary | Odds Ratio | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Liver Neoplasms - genetics | Risk Assessment | Liver Neoplasms - drug therapy | Linear Models | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Germany | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 17, pp. 1609 - 1618
In patients with metastatic colon cancer, fluorouracil, oxaliplatin, and irinotecan plus bevacizumab, as compared with fluorouracil and irinotecan plus... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INFUSIONAL FLUOROURACIL | LEUCOVORIN | MANAGEMENT | PHASE-III | GUIDELINES | IRINOTECAN | OXALIPLATIN | CHEMOTHERAPY | FOLFIRI | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Adult | Female | Leucovorin - therapeutic use | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Treatment outcome | Care and treatment | Analysis | Colorectal cancer | Dosage and administration | Leucovorin | Fluorouracil | Colorectal carcinoma | Diarrhea | Metastasis | Survival | Patients | Clinical outcomes | Metastases | Irinotecan | Stomatitis | Chemotherapy | Neurotoxicity | Oxaliplatin | Monoclonal antibodies | Vascular endothelial growth factor | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2011, Volume 154, Issue 5, pp. 644 - 653
Summary Drug‐induced immune haemolytic anaemia is a rare but serious condition. This study investigated the possibility of drug aetiology of immune haemolytic... 
immune haemolytic anaemia | drug‐induced | Berlin case‐control surveillance study | causality assessment | case‐control study | Case-control study | Causality assessment | Berlin case-control surveillance study | Immune haemolytic anaemia | Drug-induced | AUTOANTIBODIES | CEFTRIAXONE | OXALIPLATIN | FLUDARABINE | case-control study | CHRONIC LYMPHOCYTIC-LEUKEMIA | THROMBOCYTOPENIA | drug-induced | DEPENDENT ANTIBODIES | OF-THE-LITERATURE | HEMATOLOGY | CIPROFLOXACIN | Humans | Middle Aged | Male | Case-Control Studies | Young Adult | Lorazepam - adverse effects | Antineoplastic Agents - adverse effects | Drug-Related Side Effects and Adverse Reactions | Aged, 80 and over | Adult | Female | Anti-Bacterial Agents - adverse effects | Odds Ratio | Ciprofloxacin - adverse effects | Diclofenac - adverse effects | Berlin | Vidarabine - adverse effects | Anemia, Hemolytic, Autoimmune - chemically induced | Trimethoprim, Sulfamethoxazole Drug Combination - adverse effects | Vidarabine - analogs & derivatives | Piperacillin - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anemia, Hemolytic, Autoimmune - epidemiology | Adolescent | beta-Lactams - adverse effects | Aged | Population Surveillance | Drugs | Medical colleges | Lorazepam | Beta lactamases | Immunogenetics | Ciprofloxacin | Index Medicus | Anemia | Ceftriaxone | Immunosuppressive agents | Risk factors | Diclofenac | Antibiotics | Piperacillin | fludarabine | oxaliplatin | cotrimoxazole
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2009, Volume 20, Issue 11, pp. 1842 - 1847
Background: Bevacizumab significantly improves survival when added to chemotherapy for metastatic colorectal cancer (mCRC). The Bevacizumab Expanded Access... 
Expanded access study | Chemotherapy | First line | mCRC | Metastatic colorectal cancer | Bevacizumab | expanded access study | LEUCOVORIN | PHASE-II | first line | OXALIPLATIN | FLUOROURACIL | COMBINATION | chemotherapy | TRIAL | THERAPY | ONCOLOGY | bevacizumab | metastatic colorectal cancer | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Young Adult | Antibodies, Monoclonal, Humanized | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Deoxycytidine - adverse effects | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Nature Communications, ISSN 2041-1723, 12/2018, Volume 9, Issue 1, pp. 2237 - 11
Journal Article
Annals of Oncology, ISSN 0923-7534, 5/2008, Volume 19, Issue 5, pp. 920 - 926
Background: The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free... 
Irinotecan | Colorectal | Celecoxib | First line | Capecitabine | 5-FU | SURVIVAL | irinotecan | celecoxib | PHASE-III | first line | OXALIPLATIN | FLUOROURACIL | COMBINATION | AGENT | TRIAL | capecitabine | ORAL CAPECITABINE | THERAPY | ONCOLOGY | colorectal | CYCLOOXYGENASE-2 INHIBITOR | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Shock, Septic - etiology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Diarrhea - chemically induced | Cyclooxygenase 2 Inhibitors - adverse effects | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Deoxycytidine - adverse effects | Female | Camptothecin - analogs & derivatives | Pyrazoles - adverse effects | Camptothecin - adverse effects | Double-Blind Method | Fluorouracil - analogs & derivatives | Cyclooxygenase 2 Inhibitors - administration & dosage | Deoxycytidine - administration & dosage | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Pyrazoles - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Survival Analysis | Sulfonamides - adverse effects | Aged | Infusions, Intravenous | Pulmonary Embolism - chemically induced | Colorectal Neoplasms - pathology | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage
Journal Article